- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT02435056
Medication Overuse Headache (MOH) and an Innovative Approach (COMOESTAS)
Continuous Monitoring of Medication Overuse Headache in Europe and Latin America: Development and STAndardization of an Alert and Decision Support System
Přehled studie
Detailní popis
It will be a multicentre parallel group study. The two arms of the clinical protocol will be 1) classic approach to MOH and 2) Interactive Electronic Patient Record (IEPR)-based approach to MOH.
Each arm will last 12 months.
MOH will be diagnosed according to the 2006 MOH-R criteria of the International Headache Society as reported below:
A. Headache present on > 15 days/month.
B. Regular overuse for > 3 months of one or more acute symptomatic drugs:
- Ergotamine, triptans, opioids or combination analgesic medications on > 10 days/month on a regular basis for > 3 months.
- Simple analgesics or any combination of ergotamine, triptans, analgesics or opioids on > 15 days/month on a regular basis for >3 months without overuse (> 10 days) of any single class alone.
C. Headache has developed or markedly worsened during medication overuse.
The IEPR approach will be preliminarily tested and validated in small groups of patients during months 6-12 (pilot validation).
Each patient will be evaluated over a period of 7 months.
Classic approach Visit 0: patient is examined and, if suspected to suffer from MOH, is asked to fill in a diary for a month in order to quantify parameters of MOH (days with headache, acute drugs consumed, etc.). Patient has to report that MOH-R criteria were fulfilled for the previous 2 months.
Visit 1: Patient returns to the Centre, diary data are analyzed and recorded, and, if criteria for MOH-R diagnosis are fulfilled and exclusion criteria are ruled out , patient is enrolled in COMOESTAS protocol.
Detoxification: following visit 1, patient undergoes detoxification according to the protocol in Appendix 1. In the subsequent 2 months the patient is instructed to record headache characteristics and consumption of symptomatic drugs on a paper diary.
Visit 2 (2 months after detoxification): patient is visited again; diary is checked; if therapy is successful (patient no longer overuses acute medications for headache) the patient is scheduled for a follow-up visit after 4 months. The patient is asked to keep up recording headache characteristics and consumption of symptomatic drugs on a paper diary for the next 4 months and informed about a telephone contact after 2 months.
Visit 3 (6 months after detoxification): patient is visited again, diary data are collected. Study ends.
IEPR approach Visit 0: patient is examined and, if the minimum data set of the IEPR for MOH is satisfied, the patients is asked to record the headache characteristics as well as acute drugs consumption on a paper diary for a month in order to assess baseline parameters of MOH (days with headache, acute drugs consumed, etc.).
Patient has to report that MOH-R criteria were fulfilled for the previous 2 months.
Visit 1: Patient returns to the Centre, diary data are analyzed and recorded, and, if criteria for MOH diagnosis are confirmed and criteria of exclusion are ruled out, patient is enrolled in COMOESTAS protocol .
Detoxification: following Visit 1, patient undergoes detoxification according to the same protocol adopted for the classic approach. During the detoxification phase, the patient is instructed to use the electronic diary and is then asked to fill the electronic diary on a regular basis (preferably daily or at least weekly) for the next 6 months.
Visit 2 (2 months after detoxification): patient is visited again; if therapy is successful (patient no longer overuses acute medications for headache), MOH diagnosis the patient is scheduled for a follow-up visit after 4 months and informed about a telephone contact after 2 months. The patient is asked to keep up filling the electronic diary for the next 4 months.
Visit 3: the patient is visited again. Study ends.
Typ studie
Zápis (Aktuální)
Fáze
- Nelze použít
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
Patients with MOH
Exclusion Criteria:
- a current diagnosis of co-existent, significant and complicating medical or psychiatric illnesses
- significant overuse of "pure" opioids (patients overusing combination drugs containing opioids are allowed), benzodiazepines, and barbiturates,
- overuse of alcohol and other drugs of addiction,
- current treatment with migraine prophylactic drugs
- inefficacy of previous adequate detoxification programmes
- inability to provide reliable information about medical history
- pregnancy or breast feeding
- inability to learn how to use paper or electronic diaries
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Podpůrná péče
- Přidělení: Nerandomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Žádný zásah: Classic Approach
Patient fills in a paper diary in order to quantify parameters of MOH (days with headache, acute drugs consumed, etc.)
|
|
|
Experimentální: IEPR Approach
Patient has to use the electronic diary to record days with headache, acute drugs consumed, etc.
|
Adoption of Interactive Electronic Patient Record (IEPR) that consists of the following clinically-relevant main components:
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Relapse Rate Follow up
Časové okno: 6 month
|
Relapse Rate 6 months after withdrawal of patients with medication overuse.
Relapse will be defined as use of ergotamine, triptans, opioids or combination analgesic medications on > 10 days/month or use of simple analgesics or any combination of ergotamine, triptans, analgesics or opioids on > 15 days/month during the previous month, with the exclusion of month +1.
|
6 month
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Days with headache
Časové okno: 6 month
|
Number of days with headache before and after detoxification in the two arms (month -1 vs. month +6)
|
6 month
|
|
Days per month with migraine
Časové okno: 6 month
|
Number of days per month with migraine before and after detoxification in the two arms (month -1 vs. month +6)
|
6 month
|
|
MOH patients/total number of headache
Časové okno: 12 month
|
Number of MOH patients/total number of headache patients during the recruitment period (6-12 months ) of the two arms
|
12 month
|
|
MOH patients/total number of headache
Časové okno: 24 month
|
Number of MOH patients/total number of headache patients during the recruitment period (18-24 months ) of the two arms
|
24 month
|
|
Drop-outs
Časové okno: 24 month
|
Number of drop-outs in the two arms
|
24 month
|
|
Midas scores
Časové okno: 24 month
|
Changes in Midas scores in the two arms
|
24 month
|
|
HURT scores
Časové okno: 24 month
|
Changes in HURT scores in the two arms
|
24 month
|
Spolupracovníci a vyšetřovatelé
Vyšetřovatelé
- Ředitel studie: Giuseppe Nappi, MD, IRCCS Fondazione Istituto Neurologico Nazionale C. Mondino, Pavia, ITALY
- Vrchní vyšetřovatel: Rigmor Jensen, MD, PhD, Glostrup Hospital, Copenaghen, Denmark
- Vrchní vyšetřovatel: Zaza Katsarava, MD, PHD, MSc, Universitaetsklinikum, Essen, Germany
- Vrchní vyšetřovatel: Jorge Leston, MD, Fundacion para la Lucha contra las Enfermedades Neurologicas de la Infancia, Argentina
- Vrchní vyšetřovatel: Ricardo Fadic, MD, Pontificia Universidad Catolica de Chile
- Vrchní vyšetřovatel: Miguel JA Lainez, MD, PhD, Fundacion de la Comunidad Valenciana para la Investigacion Biomedica, la Docencia Y la Cooperacion Internacional y para el Desarrollo del Hospital Clinico Universitario De Valencia, Spain
- Vrchní vyšetřovatel: Marco Pagani, Manager, Consorzio di Bioingegneria Medica, Pavia, Italy
- Vrchní vyšetřovatel: Nestor Gorini, Ministerio de la Salud de la Provincia de Buenos Aires, Argentina
- Vrchní vyšetřovatel: Santiago Spadafora, Fundacion Isalud, Buenos Aires, Argentina
Publikace a užitečné odkazy
Obecné publikace
- Diener HC, Limmroth V. Medication-overuse headache: a worldwide problem. Lancet Neurol. 2004 Aug;3(8):475-83. doi: 10.1016/S1474-4422(04)00824-5.
- Headache Classification Committee; Olesen J, Bousser MG, Diener HC, Dodick D, First M, Goadsby PJ, Gobel H, Lainez MJ, Lance JW, Lipton RB, Nappi G, Sakai F, Schoenen J, Silberstein SD, Steiner TJ. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia. 2006 Jun;26(6):742-6. doi: 10.1111/j.1468-2982.2006.01172.x.
- Rossi P, Di Lorenzo C, Faroni J, Cesarino F, Nappi G. Advice alone vs. structured detoxification programmes for medication overuse headache: a prospective, randomized, open-label trial in transformed migraine patients with low medical needs. Cephalalgia. 2006 Sep;26(9):1097-105. doi: 10.1111/j.1468-2982.2006.01175.x.
- Zeeberg P, Olesen J, Jensen R. Discontinuation of medication overuse in headache patients: recovery of therapeutic responsiveness. Cephalalgia. 2006 Oct;26(10):1192-8. doi: 10.1111/j.1468-2982.2006.01190.x.
- Zeeberg P, Olesen J, Jensen R. Probable medication-overuse headache: the effect of a 2-month drug-free period. Neurology. 2006 Jun 27;66(12):1894-8. doi: 10.1212/01.wnl.0000217914.30994.bd. Epub 2006 May 17.
- Haag G, Baar H, Grotemeyer KH, Pfaffenrath V, Ribbat MJ, Diener HC. [Prophylaxis and treatment of drug-induced persistent headache. Therapy recommendation of the German Society for Migraine and Headache]. Schmerz. 1999 Feb 18;13(1):52-7. doi: 10.1007/s004829900016. No abstract available. German.
- Jellestad PL, Carlsen LN, Westergaard ML, Munksgaard SB, Bendtsen L, Lainez M, Fadic R, Katsarava Z, Goicochea MT, Spadafora S, Jensen RH, Nappi G, Tassorelli C; COMOESTAS Consortium. Economic benefits of treating medication-overuse headache - results from the multicenter COMOESTAS project. Cephalalgia. 2019 Feb;39(2):274-285. doi: 10.1177/0333102418786265. Epub 2018 Jul 8. Erratum In: Cephalalgia. 2019 Oct;39(11):1472.
- Tassorelli C, Jensen R, Allena M, De Icco R, Katsarava Z, Miguel Lainez J, Leston JA, Fadic R, Spadafora S, Pagani M, Nappi G; COMOESTAS Consortium. The added value of an electronic monitoring and alerting system in the management of medication-overuse headache: A controlled multicentre study. Cephalalgia. 2017 Oct;37(12):1115-1125. doi: 10.1177/0333102416660549. Epub 2016 Jul 20.
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Odhad)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- 215366
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na IEPR Approach
-
Farapulse, Inc.DokončenoParoxysmální fibrilace síníČesko, Francie
-
Farapulse, Inc.DokončenoParoxysmální fibrilace síníFrancie
-
Johns Hopkins Bloomberg School of Public HealthUnited States Agency for International Development (USAID)DokončenoDeprese | Posttraumatická stresová poruchaUkrajina
-
University of TennesseeNeznámýIntraartikulární zlomeninySpojené státy
-
Cairo UniversityNábor
-
University of British ColumbiaCanadian Diabetes AssociationDokončeno
-
Karolinska InstitutetNáborPoruchy užívání látek | Kriminální chováníŠvédsko
-
Samsung Medical CenterDokončenoRakovina štítné žlázyKorejská republika
-
Adai Technology (Beijing) Co., Ltd.DokončenoZávislost, látkaČína
-
Issa, Abdulhamid Sayed, M.D.DokončenoSyndrom karpálního tunelu | CTS | Uvolnění karpálního tunelu | Operace karpálního tunelu | Příčný přístup karpálního tuneluSyrská Arabská republika